NEULAND LAB LTD. Financial Ratios
NEULANDLAB · Healthcare · Current price ₹18,434
P/E ratio
65.0x
P/B ratio
13.4x
ROE
21.4%
ROCE
27.0%
Debt / Equity
0.16
Dividend yield
0.2%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 65.0x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 13.4x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 21.4% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 27.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.16 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with NEULAND LAB LTD.'s latest numbers.
NEULAND LAB LTD. profitability
NEULAND LAB LTD. generates a return on equity of 21.4% and a return on capital employed of 27.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.16 and a P/E of 65.0x, NEULAND LAB LTD. is conservatively financed. Our overall business-quality score for the company is 5.9 / 10.
Understand the ratios
More on NEULAND LAB LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.